[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100396983":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":19,"centralContacts":30,"locations":40,"responsibleParty":63,"collaborators":19,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":75,"minAge":76,"maxAge":19,"enrollmentInfo":77,"targetDuration":19,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":43,"whyStopped":19,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Augusta University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Individuals with type 1 diabetes","EXPERIMENTAL","Individuals with type 1 diabetes will be randomly assigned to 1 of the 2 interventions (Resveratrol or placebo)",[13,14],"Drug: Resveratrol","Other: Placebo",{"label":16,"type":17,"description":18,"interventionNames":19},"Healthy Controls","NO_INTERVENTION","Healthy individuals who participate will receive no intervention and serve as controls.",null,[21,26],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":19},"DRUG","Resveratrol","500 mg of oral trans-resveratrol twice daily (in the morning and evening) for 12-weeks",[9],{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":19},"Placebo","placebo for 12 weeks",[9],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":19,"email":35},"Ryan A Harris, PhD, CEP","CONTACT","7067215998","ryharris@augusta.edu",{"name":37,"role":33,"phone":38,"phoneExt":19,"email":39},"Jacob Looney, MS","7067215483","jlooney@augusta.edu",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Augusta University\u002FGeorgia Prevention Institute\u002F Laboratory of Integrative and Exercise Physiology","RECRUITING","Augusta","Georgia","30912","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-81.97484,33.47097,{"lat":53,"lon":52},[56,59],{"name":57,"role":33,"phone":58,"phoneExt":19,"email":35},"Ryan Harris, PhD, CEP","706-721-5998",{"name":60,"role":33,"phone":61,"phoneExt":19,"email":62},"Casey Derella, BS","706-721-5483","cderella@augusta.edu",{"type":64,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Ryan Harris","Associate Professor","100396983","early-phase-1-type-1-diabetes-endothelin-and-skeletal-muscle-mitochondrial-dysfunction-the-role-of-sirtuin-1-100396983",false,"NCT04449198","Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1","T-St1M","Inclusion Criteria:\n\n* Men and premenopausal women\n* All races\n* Clinical diagnosis of insulin-dependent type 1 diabetes (patients only)\n\nExclusion Criteria:\n\n* Clinical diagnosis of hepatic, cardiovascular, or renal disease\n* Uncontrolled diabetes (HbA1C \\>12%)\n* Diabetic complications (i.e. neuropathy)\n* Uncontrolled hypertension (\\>140\u002F90 mm Hg on therapy)\n* Pregnancy\n* Use of vasoactive medications",true,"ALL","18 Years",{"count":78,"type":79},24,"ESTIMATED","INTERVENTIONAL",[82],"EARLY_PHASE1","The proposed study is designed to test the hypothesis that treatment of resveratrol for 12 weeks will improve both endothelin-B receptor (aim 1) and skeletal muscle mitochondrial function (aim 2) in people with type 1 diabetes.",[85],"Type 1 Diabetes",[87,88,89,90],"diabetes","heart disease","muscle function","blood vessels","2025-01-27",{"date":93,"type":94},"2025-01-28","ACTUAL",{"date":96,"type":94},"2020-10-14",{"date":98,"type":79},"2027-07-01",{"name":5,"class":6},1]